Brandywine Trust Co buys $15,108,007 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Brandywine Trust Co scooped up 65,000 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 224,855 shares of AbbVie Inc which is valued at $15,108,007.AbbVie Inc makes up approximately 10.32% of Brandywine Trust Co’s portfolio.

Other Hedge Funds, Including , Tiaa Cref Investment Management reduced its stake in ABBV by selling 306,189 shares or 3.74% in the most recent quarter. The Hedge Fund company now holds 7,888,163 shares of ABBV which is valued at $530,005,672. AbbVie Inc makes up approx 0.39% of Tiaa Cref Investment Management’s portfolio.Martingale Asset Management L P boosted its stake in ABBV in the latest quarter, The investment management firm added 61,792 additional shares and now holds a total of 104,884 shares of AbbVie Inc which is valued at $7,047,156. AbbVie Inc makes up approx 0.11% of Martingale Asset Management L P’s portfolio.Penobscot Investment Management Company boosted its stake in ABBV in the latest quarter, The investment management firm added 3,854 additional shares and now holds a total of 83,963 shares of AbbVie Inc which is valued at $5,560,869. AbbVie Inc makes up approx 1.94% of Penobscot Investment Management Company’s portfolio.Gofen Glossberg Il reduced its stake in ABBV by selling 5,198 shares or 2.18% in the most recent quarter. The Hedge Fund company now holds 232,754 shares of ABBV which is valued at $15,075,477. AbbVie Inc makes up approx 0.62% of Gofen Glossberg Il’s portfolio.

AbbVie Inc closed down -0.1 points or -0.15% at $64.51 with 50,99,249 shares getting traded on Monday. Post opening the session at $64.84, the shares hit an intraday low of $64.19 and an intraday high of $65.09 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *